Skip to main content
SpringerLink
Log in

Neurokinin-1 Antagonists for Postoperative Nausea and Vomiting

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Postoperative nausea and vomiting (PONV) are the second most frequent adverse events after surgery second only to postoperative pain. Despite the advances in antiemetics and implementation of multimodal prophylactic interventions, the clinical management of PONV remains problematic. Neurokinin-1 (NK-1) receptor is a tachykinin receptor found throughout the central and peripheral nervous systems, with a particular affinity towards substance P. NK-1 receptors interact with several parts of the neuronal pathway for nausea and vomiting. This includes the chemoreceptor trigger zone, the gastrointestinal tract, and dorsal motor nucleus of the vagus. NK-1 antagonists are thought to prevent nausea and vomiting by downregulating the emetogenic signals at those points. As more head-to-head trials are conducted between the various anti-emetics, there is emerging evidence that NK-1 antagonists may be more effective in preventing PONV than several other antiemetics currently in use. In this review, we will discuss the pharmacology of NK-1 antagonists, their efficacy in clinical practice, and how they could fit into the framework of PONV management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gan TJ, Belani KG, Bergese S, Chung F, Diemunsch P, Habib AS, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2020;131(2):411–48.

    Article  PubMed  Google Scholar 

  2. Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014;118(1):85–113.

    Article  PubMed  Google Scholar 

  3. Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999;91(3):693–700.

    Article  CAS  PubMed  Google Scholar 

  4. Ryu JH, Sohn IS, Do SH. Controlled hypotension for middle ear surgery: a comparison between remifentanil and magnesium sulphate. Br J Anaesth. 2009;103(4):490–5.

    Article  CAS  PubMed  Google Scholar 

  5. Vari A, Gazzanelli S, Cavallaro G, De Toma G, Tarquini S, Guerra C, et al. Post-operative nausea and vomiting (PONV) after thyroid surgery: a prospective, randomized study comparing totally intravenous versus inhalational anesthetics. Am Surg. 2010;76(3):325–8.

    Article  PubMed  Google Scholar 

  6. Koivuranta M, Laara E, Snare L, Alahuhta S. A survey of postoperative nausea and vomiting. Anaesthesia. 1997;52(5):443–9.

    Article  CAS  PubMed  Google Scholar 

  7. Parra-Sanchez I, Abdallah R, You J, Fu AZ, Grady M, Cummings K 3rd, et al. A time-motion economic analysis of postoperative nausea and vomiting in ambulatory surgery. Can J Anaesth. 2012;59(4):366–75.

    Article  PubMed  Google Scholar 

  8. Berger ER, Huffman KM, Fraker T, Petrick AT, Brethauer SA, Hall BL, et al. Prevalence and risk factors for bariatric surgery readmissions: findings from 130,007 admissions in the metabolic and bariatric surgery accreditation and quality improvement program. Ann Surg. 2018;267(1):122–31.

    Article  PubMed  Google Scholar 

  9. Pierre S, Whelan R. Nausea and vomiting after surgery. BJA Educ. 2012;13(1):28–32.

    Google Scholar 

  10. Weibel S, Rücker G, Eberhart LH, Pace NL, Hartl HM, Jordan OL, et al. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. Cochrane Database Syst Rev. 2020;10:Cd012859.

    PubMed  Google Scholar 

  11. Babic T, Browning KN. The role of vagal neurocircuits in the regulation of nausea and vomiting. Eur J Pharmacol. 2014;5(722):38–47.

    Article  CAS  Google Scholar 

  12. Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur J Pharmacol. 1999;375(1–3):51–60.

    Article  CAS  PubMed  Google Scholar 

  13. Carpenter DO, Briggs DB, Strominger N. Behavioral and electrophysiological studies of peptide-induced emesis in dogs. Fed Proc. 1984;43(15):2952–4.

    CAS  PubMed  Google Scholar 

  14. Carpenter DO, Briggs DB, Strominger N. Peptide-induced emesis in dogs. Behav Brain Res. 1984;11(3):277–81.

    Article  CAS  PubMed  Google Scholar 

  15. Knox AP, Strominger NL, Battles AH, Carpenter DO. Behavioral studies of emetic sensitivity in the ferret. Brain Res Bull. 1993;31(5):477–84.

    Article  CAS  PubMed  Google Scholar 

  16. Carpenter DO, Briggs DB, Strominger N. Responses of neurons of canine area postrema to neurotransmitters and peptides. Cell Mol Neurobiol. 1983;3(2):113–26.

    Article  CAS  PubMed  Google Scholar 

  17. Qian QH, Yue W, Chen WH, Yang ZH, Liu ZT, Wang YX. Effect of gingerol on substance P and NK1 receptor expression in a vomiting model of mink. Chin Med J. 2010;123(4):478–84.

    CAS  PubMed  Google Scholar 

  18. Ray AP, Chebolu S, Darmani NA. Receptor-selective agonists induce emesis and Fos expression in the brain and enteric nervous system of the least shrew (Cryptotis parva). Pharmacol Biochem Behav. 2009;94(1):211–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Tattersall FD, Rycroft W, Francis B, Pearce D, Merchant K, MacLeod AM, et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology. 1996;35(8):1121–9.

    Article  CAS  PubMed  Google Scholar 

  20. Watson JW, Gonsalves SF, Fossa AA, McLean S, Seeger T, Obach S, et al. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol. 1995;115(1):84–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Dixon MK, Nathan NA, Hornby PJ. Immunocytochemical distribution of neurokinin 1 receptor in rat dorsal vagal complex. Peptides. 1998;19(5):913–23.

    Article  CAS  PubMed  Google Scholar 

  22. Sun X, Xu L, Guo F, Luo W, Gao S, Luan X. Neurokinin-1 receptor blocker CP-99 994 improved emesis induced by cisplatin via regulating the activity of gastric distention responsive neurons in the dorsal motor nucleus of vagus and enhancing gastric motility in rats. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2017;29(10):1–11.

    CAS  Google Scholar 

  23. Lewis MW, Travagli RA. Effects of substance P on identified neurons of the rat dorsal motor nucleus of the vagus. Am J Physiol Gastrointest Liver Physiol. 2001;281(1):G164–72.

    Article  CAS  PubMed  Google Scholar 

  24. Quartara L, Maggi CA. The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides. 1998;32(1):1–49.

    Article  CAS  PubMed  Google Scholar 

  25. Li C, Micci MA, Murthy KS, Pasricha PJ. Substance P is essential for maintaining gut muscle contractility: a novel role for coneurotransmission revealed by botulinum toxin. Am J Physiol Gastrointest Liver Physiol. 2014;306(10):G839–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Yates BJ, Catanzaro MF, Miller DJ, McCall AA. Integration of vestibular and emetic gastrointestinal signals that produce nausea and vomiting: potential contributions to motion sickness. Exp Brain Res. 2014;232(8):2455–69.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Diemunsch P, Gan TJ, Philip BK, Girao MJ, Eberhart L, Irwin MG, et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. Br J Anaesth. 2007;99(2):202–11.

    Article  CAS  PubMed  Google Scholar 

  28. Gan TJ, Apfel CC, Kovac A, Philip BK, Singla N, Minkowitz H, et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg. 2007;104(5):1082–9.

    Article  CAS  PubMed  Google Scholar 

  29. Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg PL, et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol. 2006;46(3):291–300.

    Article  CAS  PubMed  Google Scholar 

  30. Ibrahim MA, Preuss CV. Antiemetic neurokinin-1 receptor blockers. Treasure Island: StatPearls Publishing LLC; 2020.

    Google Scholar 

  31. Singh PM, Borle A, Rewari V, Makkar JK, Trikha A, Sinha AC, et al. Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. Postgrad Med J. 2016;92(1084):87–98.

    Article  CAS  PubMed  Google Scholar 

  32. Moon HY, Baek CW, Choi GJ, Shin HY, Kang H, Jung YH, et al. Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial. BMC Anesthesiol. 2014;14:68.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Liu M, Zhang H, Du BX, Xu FY, Zou Z, Sui B, et al. Neurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94(19):e762.

    Article  CAS  Google Scholar 

  34. Ham SY, Shim YH, Kim EH, Son MJ, Park WS, Lee JS. Aprepitant for antiemesis after laparoscopic gynaecological surgery: a randomised controlled trial. Eur J Anaesthesiol. 2016;33(2):90–5.

    Article  CAS  PubMed  Google Scholar 

  35. Lim CS, Ko YK, Kim YH, Park SI, Kim JK, Kim MJ, et al. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting. Korean J Anesthesiol. 2013;64(3):212–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Vallejo MC, Phelps AL, Ibinson JW, Barnes LR, Milord PJ, Romeo RC, et al. Aprepitant plus ondansetron compared with ondansetron alone in reducing postoperative nausea and vomiting in ambulatory patients undergoing plastic surgery. Plast Reconstr Surg. 2012;129(2):519–26.

    Article  CAS  PubMed  Google Scholar 

  37. Sinha AC, Singh PM, Williams NW, Ochroch EA, Goudra BG. Aprepitant’s prophylactic efficacy in decreasing postoperative nausea and vomiting in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2014;24(2):225–31.

    Article  PubMed  Google Scholar 

  38. Lee SJ, Lee SM, Kim SI, Ok SY, Kim SH, Park SY, et al. The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone. Korean J Anesthesiol. 2012;63(3):221–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kawano H, Matsumoto T, Hamaguchi E, Manabe S, Nakagawa M, Yamada A, et al. Antiemetic efficacy of combined aprepitant and dexamethasone in patients at high-risk of postoperative nausea and vomiting from epidural fentanyl analgesia. Minerva Anestesiol. 2015;81(4):362–8.

    CAS  PubMed  Google Scholar 

  40. Yoo JH, Kim SI, Chung JW, Jun MR, Han YM, Kim YJ. Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia. Korean J Anesthesiol. 2018;71(6):440–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. de Morais LC, Sousa AM, Flora GF, Grigio TR, Guimarães GMN, Ashmawi HA. Aprepitant as a fourth antiemetic prophylactic strategy in high-risk patients: a double-blind, randomized trial. Acta Anaesthesiol Scand. 2018;62(4):483–92.

    Article  PubMed  CAS  Google Scholar 

  42. Spaniolas K, Nie L, Moller D, Tatarian T, Hesketh A, Yang J, et al. A comprehensive approach for the prevention of nausea and vomiting following sleeve gastrectomy: a randomized controlled trial. Obes Surg. 2020;30(11):4250–7.

    Article  PubMed  Google Scholar 

  43. Grigio TR, Sousa AM, Magalhães GGN, Ashmawi HA, Vieira JE. Aprepitant plus palonosetron for the prevention of postoperative nausea and vomiting after breast cancer surgery: a double blind, randomized trial. Clinics (Sao Paulo, Brazil). 2020;75:e1688.

    Article  Google Scholar 

  44. Noguchi T, Umezaki Y, Takano R, Fujimoto T, Domon Y, Kubota K, et al. A novel [5.2.1]bicyclic amine is a potent analgesic without µ opioid activity. Bioorg Med Chem Lett. 2021;36:127790.

    Article  CAS  PubMed  Google Scholar 

  45. Liu Y, Hu Q, Yang J. Oliceridine for the management of acute postoperative pain. Ann Pharmacother. 2021;11:1060028020987679.

    Google Scholar 

  46. Navari RM. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2008;8(11):1733–42.

    Article  CAS  PubMed  Google Scholar 

  47. Colon-Gonzalez F, Kraft WK. Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert Opin Drug Metab Toxicol. 2010;6(10):1277–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Kakuta N, Kume K, Hamaguchi E, Tsutsumi R, Mita N, Tanaka K, et al. The effects of intravenous fosaprepitant and ondansetron in the prevention of postoperative nausea and vomiting in patients who underwent lower limb surgery: a prospective, randomized, double-blind study. J Anesth. 2015;29(6):836–41.

    Article  PubMed  Google Scholar 

  49. Murakami C, Kakuta N, Kume K, Sakai Y, Kasai A, Oyama T, et al. A comparison of fosaprepitant and ondansetron for preventing postoperative nausea and vomiting in moderate to high risk patients: a retrospective database analysis. Biomed Res Int. 2017;2017:5703528.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Tsutsumi YM, Kakuta N, Soga T, Kume K, Hamaguchi E, Tsutsumi R, et al. The effects of intravenous fosaprepitant and ondansetron for the prevention of postoperative nausea and vomiting in neurosurgery patients: a prospective, randomized, double-blinded study. BioMed Res Int. 2014;2014:307025.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Soga T, Kume K, Kakuta N, Hamaguchi E, Tsutsumi R, Kawanishi R, et al. Fosaprepitant versus ondansetron for the prevention of postoperative nausea and vomiting in patients who undergo gynecologic abdominal surgery with patient-controlled epidural analgesia: a prospective, randomized, double-blind study. J Anesth. 2015;29(5):696–701.

    Article  PubMed  Google Scholar 

  52. Atsuta J, Inoue S, Tanaka Y, Abe K, Nakase H, Kawaguchi M. Fosaprepitant versus droperidol for prevention of PONV in craniotomy: a randomized double-blind study. J Anesth. 2017;31(1):82–8.

    Article  PubMed  Google Scholar 

  53. Ottoboni T, Keller MR, Cravets M, Clendeninn N, Quart B. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a phase I, open-label, randomized, two-way crossover evaluation. Drug Des Dev Ther. 2018;12:429–35.

    Article  CAS  Google Scholar 

  54. Walton GD. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Adv Ther. 2019;36(3):662–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Ottoboni T, Lauw M, Keller MR, Cravets M, Manhard K, Clendeninn N, et al. HTX-019 via 2-min injection or 30-min infusion in healthy subjects. Future Oncol (Lond, Engl). 2019;15(8):865–74.

    Article  CAS  Google Scholar 

  56. Navari RM. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Expert Opin Drug Saf. 2020;19(2):205–10.

    Article  CAS  PubMed  Google Scholar 

  57. Navari RM, Mosier MC. Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy. Onco Targets Ther. 2019;12:3277–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Fakira AK, Devi LA, Kennedy PJ. Novel application for G protein-biased Mu opioid receptor agonists in opioid relapse prevention. Biol Psychiatry. 2020;88(12):896–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Highlights of prescribing information-Varubi (rolapitant). 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208399s000lbl.pdf. Accessed 1 Jan 2021.

  60. Ahmed H, Hammad AM, Abushouk AI, Zidan M, Salem M, Negida A, et al. Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting. Curr Probl Cancer. 2018;42(2):241–55.

    Article  PubMed  Google Scholar 

  61. Gan T, Gu J, Singla N, Chung F, Pearman M, Bergese S, et al. Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial. Anesth Analg. 2011;112(4):804–12.

    Article  CAS  PubMed  Google Scholar 

  62. Pellegatti M, Bordini E, Fizzotti P, Roberts A, Johnson B. Disposition and metabolism of radiolabeled casopitant in humans. Drug Metab Dispos Biol Fate Chem. 2009;37(8):1635–45.

    Article  CAS  PubMed  Google Scholar 

  63. Singla N, Singla S, Chung F, Kutsogiannis D, Blackburn L, Lane S, et al. Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. Anesthesiology. 2010;113(1):74–82.

    Article  CAS  PubMed  Google Scholar 

  64. Altorjay A, Melson T, Chinachoit T, Kett A, Aqua K, Levin J, et al. Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study. Arch Surg. 2011;146(2):201–6.

    Article  PubMed  Google Scholar 

  65. Brigandi R, Russ S, Petit C, Johnson B, Croy S, Hodsman P, et al. Intravenous pharmacokinetics, local tolerability, and hemolysis of an SBE7-β-cyclodextrin formulation of the neurokinin-1 receptor antagonist vestipitant. Clin Pharmacol Drug Dev. 2015;4(2):130–6.

    Article  CAS  PubMed  Google Scholar 

  66. Kranke P, Thompson J, Dalby P, Eberhart L, Novikova E, Johnson B, et al. Comparison of vestipitant with ondansetron for the treatment of breakthrough postoperative nausea and vomiting after failed prophylaxis with ondansetron. Br J Anaesth. 2015;114(3):423–9.

    Article  CAS  PubMed  Google Scholar 

  67. Diemunsch P, Schoeffler P, Bryssine B, Cheli-Muller L, Lees J, McQuade B, et al. Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. Br J Anaesth. 1999;82(2):274–6.

    Article  CAS  PubMed  Google Scholar 

  68. Gesztesi Z, Scuderi P, White P, Wright W, Wender R, D’Angelo R, et al. Substance P (Neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures. Anesthesiology. 2000;93(4):931–7.

    Article  CAS  PubMed  Google Scholar 

  69. Lucot JB. Effects of naloxone on motion sickness in cats alone and with broad spectrum antiemetics. Auton Neurosci Basic Clin. 2017;202:97–101.

    Article  CAS  Google Scholar 

  70. Ormel G, Romundstad L, Lambert-Jensen P, Stubhaug A. Dexamethasone has additive effect when combined with ondansetron and droperidol for treatment of established PONV. Acta Anaesthesiol Scand. 2011;55(10):1196–205.

    Article  CAS  PubMed  Google Scholar 

  71. Choi YS, Sohn HM, Do SH, Min KT, Woo JH, Baik HJ. Comparison of ramosetron and ondansetron for the treatment of established postoperative nausea and vomiting after laparoscopic surgery: a prospective, randomized, double-blinded multicenter trial. Ther Clin Risk Manag. 2018;14:601–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Candiotti KA, Kranke P, Bergese SD, Melson TI, Motsch J, Siddiqui N, et al. Randomized, double-blind, placebo-controlled study of intravenous amisulpride as treatment of established postoperative nausea and vomiting in patients who have had no prior prophylaxis. Anesth Analg. 2019;128(6):1098–105.

    Article  CAS  PubMed  Google Scholar 

  73. Habib AS, Gan TJ. The effectiveness of rescue antiemetics after failure of prophylaxis with ondansetron or droperidol: a preliminary report. J Clin Anesth. 2005;17(1):62–5.

    Article  CAS  PubMed  Google Scholar 

  74. Chan MTV, Choi KC, Gin T, Chui PT, Short TG, Yuen PM, et al. The additive interactions between ondansetron and droperidol for preventing postoperative nausea and vomiting. Anesth Analg. 2006;103(5):1155–62.

    Article  CAS  PubMed  Google Scholar 

  75. Fick D, Semla T, Steinman M, Beizer J, Brandt N, Dombrowski R, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94.

    Article  Google Scholar 

  76. Marbury TC, Jin B, Panebianco D, Murphy MG, Sun H, Evans JK, et al. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects. Anesth Analg. 2009;109(2):418–25.

    Article  CAS  PubMed  Google Scholar 

  77. Myles PS, Williams DL, Hendrata M, Anderson H, Weeks AM. Patient satisfaction after anaesthesia and surgery: results of a prospective survey of 10,811 patients. Br J Anaesth. 2000;84(1):6–10.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesiology, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, 11794-8480, USA

    Zhaosheng Jin, Neil Daksla & Tong J. Gan

Authors
  1. Zhaosheng Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neil Daksla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tong J. Gan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tong J. Gan.

Ethics declarations

Funding

None.

Conflicts of interest/Competing interests

Tong J. Gan received honoraria from Acacia, Edwards, Masimo, Medtronic and Merck.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Author contributions

ZJ: manuscript and illustration preparation. ND: manuscript and illustration preparation. TJG: manuscript preparation and review.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jin, Z., Daksla, N. & Gan, T.J. Neurokinin-1 Antagonists for Postoperative Nausea and Vomiting. Drugs 81, 1171–1179 (2021). https://doi.org/10.1007/s40265-021-01532-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-021-01532-y

Search

Navigation